Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients (NCT05016219)
Phase 2 - The Use of Rhythmic Light Therapy to Entrain Gamma Oscillations and the Circadian System in Patients With Alzheimer's Disease
🩺 Plain-English Summary (8th-Grade Level)
Participants will randomly be placed into one of four groups and experience one of the four following conditions: (1) a placebo light that provides a 40 hertz (Hz) flicker (rhythmic light \[RL\]); (2) a placebo light with a random flicker (placebo condition for rhythmic light); (3) a light source that will stimulate the circadian system and provides a 40 Hz flicker (RL); or (4) a light source that will stimulate the circadian system and provides a random flicker (placebo condition for rhythmic light). Following a baseline week, participants will experience his/her assigned lighting condition for two hours in the morning for 8 weeks. After a 4-week washout period, a final round of assessments will be obtained. Study assessments (except for the Pittsburgh Sleep Quality Index and Montreal Cognitive Assessment) will be collected at the end of each week, for a total of 8 assessments.
Who can join: Review the eligibility criteria below.
Location: Light and Health Research Center — Menands, New York
Age range: 55 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Light and Health Research Center — Menands, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
📞 Contact the Study Coordinator
Phone: (518) 242-4603
Email: barbara.plitnick@mountsinai.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mild Cognitive Impairment
- Enhancing Frontal Lobes Plasticity in Mild Cognitive Impairment — Toronto, Ontario
- Remote Game-based Exercise Program for Cognitive and Motor Function Improvement — Los Angeles, California
- Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) — Boston, Massachusetts
- Glutathione in Mild Cognitive Impairment — Houston, Texas
- Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy — Morgantown, West Virginia
- Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease — Los Angeles, California
Explore by condition: All Mild Cognitive Impairment clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.